Lake Street Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $20
NeuroPace (NPCE) Gets a Buy From Lake Street
A Quick Look at Today's Ratings for NeuroPace(NPCE.US), With a Forecast Between $8 to $20
Cantor Fitzgerald Reiterates Overweight on NeuroPace, Maintains $18 Price Target
NeuroPace Analyst Ratings
Wells Fargo Maintains NeuroPace(NPCE.US) With Buy Rating, Cuts Target Price to $15
Lake Street Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $20
NeuroPace Analyst Ratings
Morgan Stanley Lowers Price Target on NeuroPace to $8 From $9.50, Keeps Equalweight Rating
Strong Sales Growth and Strategic Initiatives Justify Buy Rating for NeuroPace
Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating
NeuroPace's Strong Q1 Performance and Promising Growth Prospects Affirm Buy Rating
Cantor Fitzgerald Corp.: The NeuroPace (NPCE.US) rating was confirmed and adjusted from an increase in holdings to an increase in holdings rating, with a target price of $18.00.
NeuroPace Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on NeuroPace, Maintains $18 Price Target
Analysts Offer Insights on Healthcare Companies: LifeMD (LFMD), NeuroPace (NPCE) and Dynavax (DVAX)
Lake Street Sticks to Its Buy Rating for NeuroPace (NPCE)
NeuroPace Analyst Ratings
Wells Fargo Upgrades NeuroPace to Overweight From Equalweight, Raises Price Target to $20 From $16
NeuroPace Analyst Ratings